LENZ Therapeutics, Inc. will announce its first quarter 2024 financial results and business update on May 8, 2024. The company focuses on developing aceclidine-based eye drops for presbyopia. A webcast will be held to discuss the results and updates.
LENZ Therapeutics, Inc. annuncerà i risultati finanziari del primo trimestre del 2024 e gli aggiornamenti aziendali l'8 maggio 2024. La compagnia si concentra sullo sviluppo di colliri a base di aceclidina per la presbiopia. Sarà organizzato un webcast per discutere i risultati e gli aggiornamenti.
LENZ Therapeutics, Inc. anunciará los resultados financieros del primer trimestre de 2024 y las actualizaciones empresariales el 8 de mayo de 2024. La empresa se enfoca en el desarrollo de gotas oftálmicas a base de aceclidina para la presbicia. Se realizará una transmisión en línea para discutir los resultados y las actualizaciones.
LENZ Therapeutics, Inc.는 2024년 첫 분기 재무 결과와 비즈니스 업데이트를 2024년 5월 8일에 발표할 예정입니다. 이 회사는 노안을 위한 아셀리딘 기반 안약 개발에 중점을 둡니다. 결과 및 업데이트에 대해 논의하기 위해 웹캐스트가 열릴 예정입니다.
LENZ Therapeutics, Inc. annoncera ses résultats financiers pour le premier trimestre 2024 et les mises à jour de l'entreprise le 8 mai 2024. La société se concentre sur le développement de gouttes oculaires à base d'acéclidine pour la presbytie. Un webcast sera organisé pour discuter des résultats et des mises à jour.
LENZ Therapeutics, Inc. wird am 8. Mai 2024 die Finanzergebnisse des ersten Quartals 2024 und Geschäftsaktualisierungen bekannt geben. Das Unternehmen konzentriert sich auf die Entwicklung von Aceclidin-basierten Augentropfen für Presbyopie. Eine Webübertragung wird abgehalten, um die Ergebnisse und Updates zu diskutieren.
Positive
None.
Negative
None.
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update.
The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. LENZ’s product candidates, LNZ100 is a preservative-free, single-use, once-daily eye drops containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY trials as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.